Add Formweb to your mobile device
System Formulary Update
Prevnar20® (pneumococcal 20-valent conjugate vaccine)
Situation
Prevnar20® (PCV20) is a new pneumococcal vaccine product that is now a preferred pneumococcal vaccine option per the CDC. A request for formulary addition was reviewed at the January 2022 System Pharmacy and Therapeutics Committee meeting.
Background
PCV20 is a 20-valent pneumococcal conjugate vaccine. As of January 2022, PCV20 is now a preferred first-line vaccine option for adults ≥19-64 years with select chronic comorbidities and for adults ≥65 years regardless of comorbidities. Additional details in the table below.
|
Population |
Previous Recommendation |
New Recommendation |
|
Age ≥65 years |
|
|
|
No known history of pneumococcal vaccination |
1 dose PPSV23 +/- PCV13 |
1 dose PCV20 OR 1 dose PCV15 followed by PPSV23 |
|
Prior dose of PPSV23 |
1 dose PPSV23, ≥ 5 years after last dose |
1 dose PCV20 OR 1 dose PCV15 |
|
Prior dose of PCV13 |
1 dose PPSV23 |
1 dose PPSV23 (or PCV20, if PPSV23 is unavailable) |
|
Age ≥19 to 64 years with select chronic medical conditions* |
|
|
|
No known history of pneumococcal vaccination |
1 dose PCV13, followed by 1 dose PPSV23 Subsequent PPSV23 dose may be required |
1 dose PCV20 OR 1 dose PCV15 followed by PPSV23 |
|
Prior dose of PPSV23 |
1 dose PCV13 ≥1 year after PPSV23 |
1 dose PCV20 OR 1 dose PCV15 |
|
Prior dose of PCV13 |
1 dose PPSV23 |
1 dose PPSV23 (or PCV20, if PPSV23 is unavailable) |
|
Age <19 years |
No Change |
|
Assessment/Recommendations
System P&T voted to ADD Prevnar20® prefilled syringes to the UNC Health Medication Formulary.
There are no changes to the formulary status of PCV13 (Prevnar13) or PPSV23 (Pneumovax23), which may still be used in adult patients who have already initiated a pneumococcal series.
Changes Effective: TUESDAY, APRIL 12TH